Autologous Stem Cell Therapy for COPD
Chronic Obstructive Pulmonary Disease
Phase 2Active
Key Facts
About STEMGENICS
Stemgenics is a private, clinical-stage biotechnology company that has built a dual-focused business model around stem cell services and therapeutic development. Its core activities include processing and cryopreserving autologous stem cells for personal banking, while simultaneously advancing its own pipeline of investigational cell therapies for conditions like COPD and critical limb ischemia. The company appears to be in an early-revenue stage, supported by its service offerings, as it funds and progresses its therapeutic programs through clinical trials. Its integrated approach from cell collection to therapy positions it within the growing regenerative medicine market.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Technegas® for COPD | Cyclomedica | Phase 2 |
| Emeramide for COPD | EmeraMed | Phase 2 |
| Meridigen‑COPD | Meridigen Biotech | Preclinical |
| Novel Anti-inflammatory for COPD | Shenzhen Salubris Pharmaceuticals | Phase I/II |
| F528 | Gyre Therapeutics | Not Specified |